Rapamycin is used to prevent graft rejection in transplant recipients based on its ability to suppress T-cell proliferation. The drug blocks the activity of a protein known as mammalian target of ...
The researchers used the mTOR inhibitor sirolimus, which was first approved in 1999 to prevent organ rejection after kidney transplants. It had already shown promise in preclinical models of ...
He and his colleagues hypothesized that combining paxalisib, a brain-penetrant PI3K/mTOR inhibitor, with RT might improve outcomes in patients with PI3K-mutant brain metastases. The investigators ...